- $53.79m
- -$2.92m
- $31.06m
- 55
- 43
- 34
- 40
Annual balance sheet for Enzo Biochem, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2019 July 31st | 2020 July 31st | 2021 July 31st | R2022 July 31st | 2023 July 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 60.1 | 47.9 | 43.5 | 21.6 | 82.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10.7 | 9.14 | 10.2 | 4.76 | 4.81 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 81.5 | 68.8 | 70.6 | 42.8 | 98.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 14.3 | 34.4 | 33.6 | 16 | 16.7 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 107 | 113 | 114 | 75.6 | 122 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 16 | 32.8 | 26.1 | 13 | 40 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 20.6 | 54.2 | 45.1 | 21.1 | 43.4 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 86 | 58.4 | 68.6 | 54.5 | 78.5 |
| Total Liabilities & Shareholders' Equity | 107 | 113 | 114 | 75.6 | 122 |
| Total Common Shares Outstanding |